共 111 条
Organic carbon monoxide prodrug, BW-CO-111, in protection against chemically-induced gastric mucosal damage
被引:37
作者:
Bakalarz, Dominik
[1
,2
]
Surmiak, Marcin
[1
,3
]
Yang, Xiaoxiao
[4
,5
]
Wojcik, Dagmara
[1
]
Korbut, Edyta
[1
]
Sliwowski, Zbigniew
[1
]
Ginter, Grzegorz
[1
]
Buszewicz, Grzegorz
[6
]
Brzozowski, Tomasz
[1
]
Cieszkowski, Jakub
[1
]
Glowacka, Urszula
[1
]
Magierowska, Katarzyna
[1
]
Pan, Zhixiang
[4
,5
]
Wang, Binghe
[4
,5
]
Magierowski, Marcin
[1
]
机构:
[1] Jagiellonian Univ Med Coll, Dept Physiol, PL-31531 Krakow, Poland
[2] Inst Forens Res, Dept Forens Toxicol, PL-31033 Krakow, Poland
[3] Jagiellonian Univ Med Coll, Dept Internal Med, PL-31531 Krakow, Poland
[4] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA
[5] Georgia State Univ, Ctr Diagnost & Therapeut, Atlanta, GA 30303 USA
[6] Med Univ Lublin, Dept Forens Med, PL-20093 Lublin, Poland
关键词:
Gastroprotection;
Carbon monoxide;
Prodrug;
Anti-inflammation;
NSAID;
Ethanol;
Gastric mucosal damage;
HYDROGEN-SULFIDE;
CO-RELEASE;
MITOCHONDRIAL BIOGENESIS;
HEME OXYGENASE-1;
DRUG-DELIVERY;
MOLECULES;
INJURY;
DONOR;
CLICK;
INHIBITION;
D O I:
10.1016/j.apsb.2020.08.005
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Metal-based carbon monoxide (CO)-releasing molecules have been shown to exert anti-inflammatory and anti-oxidative properties maintaining gastric mucosal integrity. We are interested in further development of metal-free CO-based therapeutics for oral administration. Thus, we examine the protective effect of representative CO prodrug, BW-CO-111, in rat models of gastric damage induced by necrotic ethanol or aspirin, a representative non-steroidal anti-inflammatory drug. Treatment effectiveness was assessed by measuring the microscopic/macroscopic gastric damage area and gastric blood flow by laser flowmetry. Gastric mucosal mRNA and/or protein expressions of HMOX1, HMOX2, nuclear factor erythroid 2-related factor 2, COX1, COX2, iNos, Anxa1 and serum contents of TGFB1, TGFB2, IL1B, IL2, IL4, IL5, IL6, IL10, IL12, tumor necrosis factor a, interferon gamma, and GM-CSF were determined. CO content in gastric mucosa was assessed by gas chromatography. Pretreatment with BW-CO-111 (0.1 mg/kg, i.g.) increased gastric mucosal content of CO and reduced gastric lesions area in both models followed by increased GBF. These protective effects of the CO prodrug were supported by changes in expressions of molecular biomarkers. However, because the pathomechanisms of gastric damage differ between topical administration of ethanol and aspirin, the possible protective and anti-inflammatory mechanisms of BW-CO-111 may be somewhat different in these models. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
引用
收藏
页码:456 / 475
页数:20
相关论文